{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:23:27Z","timestamp":1790835807370,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Behringer-Ingelheim"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The RF is a representative autoantibody against the crystallizable fragment (Fc) of denatured IgG that is primarily detected in patients with RA. Although five types of TNF inhibitors can be used to treat RA, no guidelines are available for selecting the appropriate inhibitor for treatment. High serum RF levels are associated with high disease activity, progressive joint destruction, life prognosis associated with organ damage, decreased treatment responsiveness to TNF inhibitors and other drugs and low treatment retention rates. Meanwhile, certolizumab pegol (CZP), a TNF inhibitor without the Fc region, remains at high concentrations in the blood. Unlike other antibody drugs with the Fc region, CZP maintains efficacy in patients with high serum RF levels. When serum IgM-RF levels are high, antibody drugs with the Fc region are more likely to bind to IgM-RF and be degraded. Thus, CZP without the Fc region may be more favourable for patients with high serum RF levels.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaf003","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:55:23Z","timestamp":1736524523000},"page":"ii9-ii14","source":"Crossref","is-referenced-by-count":10,"title":["What is rheumatoid factor? From screening to personalized management"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"2025041108015540600_keaf003-B1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1600-0463.2007.apm_682a.x","article-title":"On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. 1939","volume":"115","author":"Waaler","year":"2007","journal-title":"APMIS"},{"key":"2025041108015540600_keaf003-B2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42358-018-0042-8","article-title":"Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis","volume":"59","author":"de Brito Rocha","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2025041108015540600_keaf003-B3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American college of rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025041108015540600_keaf003-B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025041108015540600_keaf003-B5","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2025041108015540600_keaf003-B6","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.semarthrit.2019.04.007","article-title":"Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases","volume":"48","author":"Tanaka","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025041108015540600_keaf003-B7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"2025041108015540600_keaf003-B8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025041108015540600_keaf003-B9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-024-03287-9","article-title":"Impact of multimorbidity on the first ts\/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry","volume":"26","author":"Calvo-Guti\u00e9rrez","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2025041108015540600_keaf003-B10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/1756-185X.14699","article-title":"Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: post-hoc analysis of clinical trials","volume":"26","author":"Tanaka","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"2025041108015540600_keaf003-B11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025041108015540600_keaf003-B12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.20982","article-title":"Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study","volume":"52","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025041108015540600_keaf003-B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ard.2004.023523","article-title":"Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis","volume":"64","author":"De Rycke","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025041108015540600_keaf003-B14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2014a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2025041108015540600_keaf003-B15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/acr.22642","article-title":"Cause-specific mortality in male US veterans with rheumatoid arthritis","volume":"68","author":"England","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025041108015540600_keaf003-B16","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1136\/ard.2009.110536","article-title":"Effect of rheumatoid factor on mortality and coronary heart disease","volume":"69","author":"Tomasson","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025041108015540600_keaf003-B17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-017-1401-2","article-title":"High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study","volume":"19","author":"Takeuchi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025041108015540600_keaf003-B18","first-page":"AB0638","article-title":"Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase 3B REALISTC trial","author":"Smolen","year":"2024","journal-title":"EULAR"},{"key":"2025041108015540600_keaf003-B19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.12688\/f1000research.18688.1","article-title":"Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies","volume":"8","author":"Senolt","year":"2019","journal-title":"F1000Res"},{"key":"2025041108015540600_keaf003-B20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13075-021-02547-2","article-title":"Serum TNF\u03b1 levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study","volume":"23","author":"Miyazaki","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025041108015540600_keaf003-B21","first-page":"999","article-title":"Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis","volume":"42","author":"Mart\u00ednez-Feito","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2025041108015540600_keaf003-B22","doi-asserted-by":"crossref","first-page":"e003975","DOI":"10.1136\/rmdopen-2023-003975","article-title":"Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study","volume":"10","author":"L\u00f3pez-Medina","year":"2024","journal-title":"RMD Open"},{"key":"2025041108015540600_keaf003-B23","doi-asserted-by":"crossref","first-page":"keae435-3024","DOI":"10.1093\/rheumatology\/keae435","article-title":"Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis","volume":"63","author":"Smolen","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025041108015540600_keaf003-B24","doi-asserted-by":"crossref","first-page":"1016263","DOI":"10.3389\/fimmu.2022.1016263","article-title":"Rheumatoid factor IgM autoantibodies control IgG homeostasis","volume":"13","author":"Nicol\u00f2","year":"2022","journal-title":"Front Immunol"},{"key":"2025041108015540600_keaf003-B25","doi-asserted-by":"crossref","first-page":"e0217624","DOI":"10.1371\/journal.pone.0217624","article-title":"Immunoglobulin G structure and rheumatoid factor epitopes","volume":"14","author":"Maibom-Thomsen","year":"2019","journal-title":"PLoS One"},{"key":"2025041108015540600_keaf003-B26","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fimmu.2020.01393","article-title":"Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation","volume":"11","author":"Junker","year":"2020","journal-title":"Front Immunol"},{"key":"2025041108015540600_keaf003-B27","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/imt-2016-0067","article-title":"Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications","volume":"8","author":"Levy","year":"2016","journal-title":"Immunotherapy"},{"key":"2025041108015540600_keaf003-B28","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.3390\/jcm12093271","article-title":"Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases","volume":"12","author":"Pizano-Martinez","year":"2023","journal-title":"J Clin Med"},{"key":"2025041108015540600_keaf003-B29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41584-019-0240-8","article-title":"Stratifying management of rheumatic disease for pregnancy and breastfeeding","volume":"15","author":"Giles","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025041108015540600_keaf003-B30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf003\/61407428\/keaf003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_2\/ii9\/61407428\/keaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_2\/ii9\/61407428\/keaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:02:07Z","timestamp":1744358527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/Supplement_2\/ii9\/7951329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":30,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2025,1,10]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf003","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,10]]}}}